|
Investors to Hear Directly From Companies Including Sanofi-Synthelabo, Crucell N.V., and BioSante Pharmaceuticals at Biotechnology & Pharmaceuticals Stocks Forum in NY on June 23 Harvard Bioscience, Acambis, and Viragen also to present with Lynn Sutherland, President of Sutherland Consulting and Bill Alpert, Senior Editor & Biotechnology Writer for Barron`s, Delivering Keynotes RICHMOND, Va., May 13 /PRNewswire-FirstCall/ -- Investors interested in Biotechnology and Pharmaceutical stocks will receive the latest updates at the Informed Investors Forum on June 23. This live forum will include presentations by executives from Sanofi-Sythelabo, Crucell N.V.(NASDAQ-NMS:CRXL) , BioSante Pharmaceuticals Inc., Harvard Bioscience Inc.(NASDAQ-NMS:HBIO) , Viragen Inc. and Acambis plc(NASDAQ-NMS:ACAM) . Lynn Sutherland, President of Sutherland Consulting and Bill Alpert, Senior Editor & Biotechnology Writer for Barron`s, will deliver keynote addresses. The analyst-style forum, which includes presentations from top executives of the firms, followed by question and answer sessions, will be held at The Princeton Club of NY at 15 West 43rd Street starting at 8:30 am. A webcast of the forum will be archived on www.informedinvestors.com following the close of the event. Sanofi-Synthelabo(NYSE:SNY) (NYSE: SNY) is an international pharmaceutical group engaged in the research, development, manufacture and marketing of pharmaceutical products. Crucell N.V.(NASDAQ-NMS:CRXL) (Nasdaq: CRXL) is a biotechnology company focused on developing products that prevent and treat infectious diseases. BioSante Pharmaceuticals Inc. (Amex: BPA) is an emerging pharmaceutical company developing a pipeline of hormone therapy products. Harvard Bioscience Inc.(NASDAQ-NMS:HBIO) (Nasdaq: HBIO) is a global developer, manufacturer and marketer of a range of specialized products, primarily scientific instruments, used to accelerate drug discovery research. Acambis plc(NASDAQ-NMS:ACAM) (Nasdaq: ACAM) is a leading developer of vaccines to prevent and treat infectious diseases. Its investigational smallpox vaccine is being developed for governments around the world who are looking to protect their citizens in the event of a smallpox outbreak. Viragen Inc. (Amex: VRA) is a biotechnology company specializing in the research, development and commercialization of natural and recombinant protein-based drugs designed to treat a broad range of viral and malignant diseases. Informed Investors Forums are the leading online and offline industry- specific investment conferences for investors and a member of the PrecisionIR suite of investor relations services from WILink. To register to attend the Forum, please visit http://www.informedinvestors.com/CustomEvent/85117/index.asp… Companies wanting to participate in the forum should contact Cary Loeser at cloeser@wilink.com. Fraktal |
|
| aus der Diskussion: | Viragen - aktueller Artikel im Science Magazin |
| Autor (Datum des Eintrages): | Frakt@l (13.05.04 22:10:28) |
| Beitrag: | 118 von 128 (ID:13124139) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |